Literature DB >> 27479818

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.

Roopesh Kansara1, Joseph M Connors1, Kerry J Savage1, Alina S Gerrie2, David W Scott1, Graham W Slack3, Randy D Gascoyne3, Laurie H Sehn1, Diego Villa4.   

Abstract

Entities:  

Keywords:  R-CHOP; composite lymphoma; discordant lymphoma; maintenance rituximab; transformed lymphoma

Mesh：

Substances：

Year:  2016        PMID： 27479818      PMCID： PMC5046663          DOI： 10.3324/haematol.2016.144550

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

3.  Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.

Authors:  Armin Rashidi; Eunhye Oak; Nancy L Bartlett
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  Incidence, risk factors and outcome of histological transformation in follicular lymphoma.

Authors:  Annarita Conconi; Carlotta Ponzio; Chiara Lobetti-Bodoni; Maddalena Motta; Paola M V Rancoita; Anastasios Stathis; Alden A Moccia; Luca Mazzucchelli; Francesco Bertoni; Michele Ghielmini; Franco Cavalli; Emanuele Zucca
Journal:  Br J Haematol       Date:  2012-02-20       Impact factor: 6.998

Review 5.  Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Anat Gafter-Gvili; Gilles Salles; Martin H Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Ruth Pettengell; Mathias Witzens-Harig; Ofer Shpilberg
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

6.  R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

Authors:  Massimo Federico; Stefano Luminari; Alessandra Dondi; Alessandra Tucci; Umberto Vitolo; Luigi Rigacci; Francesco Di Raimondo; Angelo Michele Carella; Alessandro Pulsoni; Francesco Merli; Luca Arcaini; Francesco Angrilli; Caterina Stelitano; Gianluca Gaidano; Matteo Dell'olio; Luigi Marcheselli; Vito Franco; Sara Galimberti; Stefano Sacchi; Maura Brugiatelli
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

7.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.

Authors:  Silvia Montoto; Andrew John Davies; Janet Matthews; Maria Calaminici; Andrew J Norton; John Amess; Sarah Vinnicombe; Rachel Waters; Ama Z S Rohatiner; T Andrew Lister
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

8.  Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

Authors:  Diego Villa; Michael Crump; Tony Panzarella; Kerry J Savage; Cynthia L Toze; Douglas A Stewart; David A MacDonald; Rena Buckstein; Christina Lee; Mohsen Alzahrani; Morel Rubinger; Ronan Foley; Anargyros Xenocostas; Mitchell Sabloff; Alexandra Muccilli; Neil Chua; Felix Couture; Jean-François Larouche; Sandra Cohen; Joseph M Connors; Kimberley Ambler; Abdulwahab Al-Tourah; Khaled M Ramadan; John Kuruvilla
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

9.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Authors:  Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors:  Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  2 in total

Review 1.  Transformed lymphoma: what should I do now?

Authors:  Sonali Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Authors:  Christian Gisselbrecht; Eric Van Den Neste
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.